NCT06157151 - PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 21, 2025

Primary Completion Date

January 30, 2028

Study Completion Date

January 30, 2028

Conditions

Cervical CancerHPV-Related CarcinomaHPV-Related MalignancyRecurrent Cervical CarcinomaMetastatic Cervical Cancer

Interventions

BIOLOGICAL

PRGN-2009 plus Pembrolizumab

Subjects randomized will receive PRGN-2009 (5 x 10\^11 PU, subcutaneous (SC) injection) every 3 weeks for three administrations, thereafter subjects will continue to receive PRGN-2009 administrations every 6 weeks. Pembrolizumab will be administered concurrently as intravenous (IV) infusion (400 mg) every 6 weeks.

DRUG

Pembrolizumab alone

Subjects randomized will receive IV infusion of pembrolizumab (400 mg) administered every 6 weeks.

Trial Locations (3)

20892

RECRUITING

National Institute of Health, Bethesda

72205

RECRUITING

University of Arkansas for Medical Sciences, Little Rock

98109

ACTIVE_NOT_RECRUITING

University of Washington, Seattle